Current Report Filing (8-k)
February 15 2017 - 04:58PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 15, 2017
INTELLIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
40 Erie Street, Suite 130
Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (857) 285-6200
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On February 15, 2017, Intellia Therapeutics, Inc. (the Company) issued a press release entitled CRISPR Therapeutics, Intellia
Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K. A copy of the press release is filed herewith as Exhibit 99.1 and is
incorporated into this Item 8.01 by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit Number
|
|
Description
|
|
|
99.1
|
|
Press release dated February 15, 2017, entitled CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding
Patents in the U.K.
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
|
Date: February 15, 2017
|
|
|
|
By:
|
|
/s/ Nessan Bermingham
|
|
|
|
|
|
|
Nessan Bermingham, Ph.D.
President and Chief
Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press release dated February 15, 2017, entitled CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding
Patents in the U.K.
|
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2023 to Mar 2024